-
Blue Shield Biotech Faces Bankruptcy Proceedings After Missing Debt Payments
•
The Nanjing Qixia District People’s Court has accepted a bankruptcy liquidation case for Blue Shield Biotech, a China-based pharmaceutical company specializing in tumor drug development. The move comes after Blue Shield Biotech failed to meet its debt obligations. As of April 9, 2024, the company’s total employee debt stood at…
-
Blue Shield Pharma’s LD013 CAR-T Therapy Approved for Clinical Trials
•
China-based Blue Shield Biotech’s in-house developed LD013, an autologous chimeric antigen receptor (CAR)-T cell therapy, has obtained clinical trial approval from the National Medical Products Administration (NMPA). The intended indication is recurrent refractory ovarian cancer, a condition that poses significant challenges in treatment and management. Mesothelin as a TargetMesothelin (MSLN)…
